Shares of Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) have climbed in the previous month. During that time period, shares are up 9.09% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.35%. Year-to-date, the stock has performed -52.00%.
Street analysts have given views on company stock . According to data from First Call, Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) has a consensus recommendation of 5.00. This recommendation falls on a scale from 1 to 5 where a 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.
Tracking some technical levels, shares are trading 6.48% away from the 50 day simple moving average and -13.09% off of the 200 day simple moving average. Recently, the stock has been noted -86.74% away from it’s 52- week high and 100.00% separated from its 52 week low. After the recent increase in the stock price, investors might also be looking to see if the stock has entered overbought territory and possibly be primed for a pullback. Traditionally, a stock is thought to be overbought when the Relative Strength Index moves above 70. As of this writing, Skystar Bio Pharmaceutical Company’s RSI stands at 52.15 . In looking at volatility levels, the shares saw weekly volatility of 14.44% and 10.88% over the past month.
Disclaimer: This article is in no way encouraging or advising whether to buy or sell the security, Being a successful investor during one time period does not mean that you will make money when you actually invest during a later time period. Market conditions constantly change. When investing in securities or options you may lose all of the money you invested. Stock trading and investing involves risk of loss to investment capital and past performance is not a guarantee of future results.
Skystar Bio Pharmaceutical Company - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.